Jerusalem Pharmaceuticals Co. Ltd. Announces Unaudited Earnings Results for the Full Year Ended December 31, 2017
Jerusalem Pharmaceuticals Co. Ltd. announced unaudited earnings results for the full year ended December 31, 2017. For the year, the company reported sales of $35,150,792 against $28,601,050 a year ago. Net income before tax was $6,287,361 against $3,230,008 a year ago. Net income after tax was $6,186,852 or $0.342 per basic and diluted share against $3,050,959 or $0.176 per basic and diluted share a year ago. Net cash flow from operating activities was $4,856,200 against $2,483,558 a year ago. Purchase of property, plant and equipment was $1,626,021 against $699,065 a year ago. Purchase of intangible assets was $305,234 against $207,657 a year ago.